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Common bile duct stones (CBDSs) may occur in up to 3%–14.7% of all patients for whom cholecystectomy is preformed. Patients
presenting with CBDS have symptoms including: biliary colic, jaundice, cholangitis, pancreatitis or may be asymptomatic . It is
important to distinguish between primary and secondary stones, because the treatment approach varies. Stones found before,
during, and after cholecystectomy had also diﬀering treatments. Diﬀerent methods have been used for the treatment of CBDS but
the suitable therapy depends on conditions such as patient’ satisfaction, number and size of stones, and the surgeons experience in
laparoscopy. Endoscopic retrograde cholangiopancreatography with or without endoscopic biliary sphincterotomy, laparoscopic
CBD exploration (transcystic or transcholedochal), or laparotomy with CBD exploration (by T-tube, C-tube insertion, or primary
closure) are the most commonly used methods managing CBDS. We will review the pathophysiology of CBDS, diagnosis, and
diﬀerent techniques of treatment with especial focus on the various surgical modalities.
Copyright © 2009 Abolfazl Shojaiefard et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
CBDSs are one of the medical conditions leading to surgical
intervention. They may occur in 3%–14.7% of all patients
for whom cholecystectomies are preformed [1, 2]. When
patients present with CBD, the one important question
that should be answered: what is the best modality of
treatment under the giving conditions? There are competing
technologies and approaches for diagnosing CBDS with
regard to diagnostic performance characteristics, technical
success, safety, and cost eﬀectiveness. Management of CBDS
usually requires two separate teams: the gastroenterologist
and the surgical team [3]. One of the main factors in
the management is initially the detection of CBDS, before,
during, or after cholecystectomy. The main options for
treatment are pre- or postoperative ERCP with endoscopic
biliary sphincterotomy (EST), laparoscopic or open surgical
bile duct clearance. There are other options for the treat-
ment of CBDS such as electrohydraulic lithotripsy (EHL),
extracorporeal shockwave lithotripsy (ESWL), dissolving
solutions, and laser lithotripsy. It is unlikely that one option
willbeappropriateforallclinicalcircumstancesinallcenters.
Variables such as disease status, patient demographics,
availabilityofendoscopic,radiologicalandsurgicalexpertise,
and healthcare economics will all have signiﬁcant inﬂuence
on practice [4].
2. Method
AMedline-based searchonallpublished papers(English and
German) for CBDS diagnosis and treatment was performed.
The search terms used for the review included common
duct stones, clinical presentation of CBDS, diagnostic
approachofCBDS,MRCP,transabdominalultrasonography,
intraoperative cholangiography, common duct exploration,
common bile duct exploration, laparoscopic common bile
duct stone endoscopic sphincterotomy, trans-cystic, and
ductal approach. This paper serves to delineate the current
relevant concepts in the varying treatments of patients that
present with CBDS. We also present a possible algorithm for
the treatment of CBDS (Figure 1).2 Gastroenterology Research and Practice
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Figure 1: Algorithm for management of common bile duct stones. LC: Laparoscopic cholecystectomy, LCD: Laparoscopic choledochotomy,
PTC: Percutaneous transhepatic catheter drainage, TC-CBDE: Transcystic common bile duct exploration, OCBDE: Open common bile duct
exploration, IOC: Intraoperative cholangiogram.
3. Pathogenesis andClinicalManifestation
CBDS can be caused either by primary bile duct stones
that originate in the bile duct or by secondary bile duct
stones that have descended from the gallbladder [6]. In the
primary stones, bilirubin is dominant component and is
associated with biliary stasis and infection. In secondary
stones, cholesterol is dominant component. It is therefore
important to distinguish between primary and secondary
stones. Cholecystectomy and choledocholithotomy are suf-
ﬁcient in the management of secondary stones, while the
presenceofprimarystonesoftennecessitatesamorecomplex
drainage procedure to prevent recurrence [7, 8]. Table 1
shows the types of bile duct stones [5]. In addition,
cholecystectomy at a young age leads to CBD dilatation and
is another acquired risk factor for CBD stones [9].
The symptoms and signs of CBDS are highly variable
andcanrangefrompatientsbeingcompletelyasymptomatic,
to complications such as cholangitis or pancreatitis [10].
Literature describes the Prevalence of asymptomatic CBDS
between 5.2% and 12% [11]. A common presentation of
CBDS is the biliary colic. Pain is often situated in the
right hypochondrium or epigastrium and can last from 30
minutes to several hours, with associated symptoms such
as nausea and vomiting [10]. Other common symptoms
include pale stools and dark-colored urine, which can be
elicitedinthepatienthistorybyathoroughreviewofsystems
[12]. Two serious complications of CBDS are cholangitis and
gallstone pancreatitis. Acute obstructive cholangitis (AOC)
is a life-threatening complication caused by an infection of
the biliary ductal system secondary to biliary obstruction.
Cultures are most often positive for E. coli, and the infection
clears in more than 75% of cases with antibiotic treatment
[13]. In cholangitis, the classic symptoms of Charcot’s triad
may be encountered, and the less common Reynold’s pentad
adds to the diagnosis [7, 13]. Despite the advancement in
treatment, AOC still carries a mortality rate of 10–20% [14].
It remained unclear for a long time why some gallstone
patients suﬀer from pancreatitis, while others are spared
from this potentially lethal complication. Recent data indi-
cate that small gallstones, excess cholesterol crystals, and
good gallbladder emptying are associated with increased risk
of pancreatitis [15, 16]. Small gall stones could lead to a
more distal obstruction with potential reﬂux of bile into the
pancreatic ducts. This could induce a common pathway of
pancreatic duct injury with release of activated pancreaticGastroenterology Research and Practice 3
Table 1: Classiﬁcation of gallstones [5].
Cholesterol Brown-pigment stone Black-pigment stone
Origin Gallbladder (secondary
stones)
Ducts ± gallbladder (primary
stones)
Gallbladder ± ducts (primary
or secondary stones)
Component 40–70% cholesterol 15% cholesterol 2% cholesterol
60% calcium bilirubinate 6% calcium carbonate
15% calcium phosphate 40% calcium bilirubinate
9% calcium phosphate
Predisposing factor
–Obesity –Diet: low protein, high
carbohydrate –Cirrhosis
–↓Bile duct pool –Cholangitis –Chronic hemolysis
–↑Cholesterol synthesis –Biliary stricture –Sickle cell anemia
–↑Progesterone –Biliary infections: bacterial,
parasitic –Heart valve replacement
–Biliary stasis: total parenteral
nutrition, vagotomy
Shape, size, number Multiple: smooth faceted Smooth, round Multiple, irregular, or smooth
Single: ≥2.5cm, smooth,
round 1–3cm usually <0.5cm
Physical
characteristics Hard, laminated Hard Soft, friable
enzymes into the glandular interstitium [17]. The majority
of these patients will have self-limiting disease, but mortality
still remains about 10% [18]. The mortality rate is less than
1% for mild acute pancreatitis, but it can approach 10% to
30% for severe acute pancreatitis [19].
4. Assessment and Diagnosis
4.1. Laboratory Tests. Patients exhibiting the described
symptoms require diagnostic investigation to assess for the
presence of CBDS [12]. Liver function tests (LFTs) can be
used to screen for CBDS [20, 21]. Elevated serum bilirubin
and alkaline phosphatase typically reﬂectbiliary obstruction,
but these are neither highly sensitive nor speciﬁc for CBDS
[22]. In a study by Anciaux et al., elevated serum gamma
glutamyl transpeptidase (GGT) and alkaline phosphatase
(ALP) were the most frequent abnormalities in laboratory
valves of patients with symptomatic CBDS [10]. Serum
bilirubin levels may be markedly elevated depending on
whether the obstruction of the bile duct is complete or
incomplete [10]. Murohisa et al. [23] and Sheen-Chen et
al. [24] in one case study reported high level CA 19-9 in
CBDS with cholangitis. Most of the studies have shown
that laboratory studies must be used in addition to imaging
modalities to predict the likelihood of CBDS, and the
multivariate analysis models have found a dilated bile duct
to be an independent variable in predicting CDBS [25–27].
4.2. Imaging Modalities
4.2.1. Transabdominal Ultrasonography (TUS). It is the ﬁrst
line investigation in patients with suspected CBDS [10].
Its sensitivity for detecting CBDS is between 25% to 63%
[28], with a speciﬁcity of approximately 95% [28] depending
on the degree of dilation of the CBD and investigators
experience. Barkun et al. reported that in patients older than
55 years with abnormal liver enzymes and CBD dilation
in ultrasound examination, CBDS is predicted in up to
95% [29]. Endoscopic retrograde cholangiopancreatography
(ERCP) is often described as the gold standard test to for
the detection of CBDS [10]. This procedure was initially
used primarily in diagnosis, but today is more commonly
used as a therapeutic modality [12]. ERCP has sensitivity
between 90% to 95% in detecting CBD stones [30, 31]a n d
a speciﬁcity of 92% to 98% [32, 33]. Christensen et al.
demonstrated that the ERCP exam has a morbidity rate of
15.9% and a mortality rate of 1% [34].
4.2.2. Endoscopic Ultrasound (EUS). It involves the endo-
scopic insertion of an ultrasound probe through the stomach
and up to the second half of the duodenum, allowing for
ultrasound images of the CBD without the interference of
subcutaneous fat and bowel gas [35]. Sensitivity of EUS
varies from 95%, while speciﬁcity is between 95–98% [36].
EUS is signiﬁcantly more sensitive than TUS in detecting
CBD stones. Its sensitivity is comparable to the diagnostic
ERCP, while its major advantage is a signiﬁcantly decreased
morbidity compared to ERCP [12, 37]. The EUS exam
is a noninvasive test, with excellent overall sensitivity and
speciﬁcity for diagnosing choledocholithiasis, but it is highly
dependent on the examiner.
4.2.3. Magnetic Resonance Cholangiopancreatography
(MRCP). It has emerged as an accurate, noninvasive4 Gastroenterology Research and Practice
diagnostic modality for investigating the biliary ducts
[22,38].Itmaybeespeciallybeneﬁcialinidentifyingpatients
who would beneﬁt from early intervention [12, 39–41]. A
recent authoritative meta-analysis of 67 published controlled
trials shows that MRCP has an excellent overall sensitivity
of 95% and a speciﬁcity of 97% for demonstrating CBDS
[42–44]. Verma et al. reported no statistically signiﬁcant
diﬀerences between EUS and MRCP in the detection rate
of CBDS [45]. Some major disadvantages of MRCP, as
compared to ERCP, are the lower spatial resolution [46], unit
availability, potential for claustrophobia, and the inability to
evaluatepatientswithpacemakersorferromagneticimplants
[42].
4.2.4. Intraoperative Cholangiography (IOC). The routine
use of IOC is still controversial. Some authors supporting
routine IOC [47, 48], while others favor selective IOC
[49, 50], and others report no advantages in IOC [51–
53] with respect to missed CBD stones. However, it can
be an useful tool to identify choledochal stones [22]. This
procedure can be performed during open or laparoscopic
cholecystectomy. IOC has a sensitivity of 98% and speciﬁcity
of 94% to detection of CBDS [54]. IOC can fail primarily
due to inability to cannulate the cystic duct. Other reasons
for failure are leakage of contrast ﬂuid during the injection,
air bubbles mimicking stones, failure to ﬁll the biliary tree
because of too rapid contrast injection into the duodenum,
and spasm of the sphincter of Oddi. Supporters of routine
IOC claim that this practice ensures fewer retained stones,
fewer postoperative ERCPs, and a reduction in the number
of CBD injuries [55, 56]. One drawback is the consequent
lengthening of the operative time by approximately 15
minutes [33, 57].
4.2.5. Conventional Computed Tomography (CT). It has a
sensitivityof87%andaspeciﬁcityof97%forthediagnosisof
CBD stones [58–60]. Kondo et al. showed that CT scanning
was equivalent to MRCP [61], with the added risk of allergic
reaction to contrast injection [62].
4.2.6. Intraductal Ultrasonography (IDUS). Although the
utility of intraductal ultrasonography (IDUS) for common
bile duct stones has been reported, the clinical signiﬁcance of
this procedure in making therapeutic decisions has not been
well clariﬁed [63]. IDUS is a valuable method for residual
small stones in the common bile duct after endoscopic
lithotripsy [64]. IDUS increases sensitivity and speciﬁcity in
the diagnosis of choledocholithiasis, and these gains are not
coupled with a notable increase in procedure time (7–15
minutes) [65]. IDUS is especially recommended in patients
who have a dilated bile duct with suspected small bile duct
stones when ERCP is not diagnostic [64].
4.2.7. Percutaneous Transhepatic Cholangiography (PTC). It
is not a routine initial diagnostic test in patients with CBD
stones [42] but is the modality of choice in patients with
previous gastric surgery, distal obstructing CBDS that failed
ERCP or in patients with cholangiohepatitis and extensive
intrahepatic stone disease. It is important to consider that
uncorrected coagulopathy is a contraindication for PTC.
5. Treatment
5.1. Medical. Patients with cholangitis or gallstone pan-
creatitis are generally acutely ill, and they often require
a g g r e s s i v er e h y d r a t i o na sw e l la sc o m p l e t eb o w e lr e s t[ 12].
Enteric gram-negative bacteria are usually cultured from
the bile of patients with acute cholangitis, especially E. coli
and Klebsiella species. In the last decades the microbiolog-
ical proﬁle has changed due to increased instrumentation
of the bile ducts and wide spread use of antibiotics in
the population. Polymicrobial bile cultures are also often
found.Anaerobicbacteriaareusuallyisolatedinconjunction
with aerobic bacteria [66]. Choice of antibiotics should
be inﬂuenced by patient characteristics (e.g., antibiotic
hypersensitivity, renal function, hearing loss, severity of
disease, previous instrumentation of the bile ducts) and
regionalantibioticsensitivitypatterns[66].Thecombination
of an aminoglycoside with amoxicillin-clavulanic acid is
primarily used as the ﬁrst-line of treatment [66]. In the event
of contraindications to aminoglycosides, broad-spectrum
penicillin (e.g., piperacillin or piperacillin-tazobactam) is a
reasonable alternative.
5.2. Intervention or Surgery. Today, therapeutic decision-
making is based on the local availability of expertise. Two
groupsofinterventionshavesigniﬁcantrolesinmanagement
of CBD stones (1) pre- or postoperative ERCP with endo-
scopicbiliarysphincterotomy(EST)ina two-stageprocedure,
(2) surgical bile duct clearance and cholecystectomy as one-
stage procedure. Several randomized controlled trials showed
similar eﬀectiveness for both methods of treatment [67,
68]. Kharbutli et al. reported that one-stage management
of symptomatic CBDS is associated with less morbidity
and mortality (7% and 0.19%) than two-stage management
(13.5% and 0.5%) [69]. Other methods include elec-
trohydraulic lithotripsy (EHL), extracorporeal shockwave
lithotripsy(ESWL),laserlithotripsy,anddissolvingsolutions
that are indicated only in special situations. Although these
techniques are useful in the management of the complicated
biliary tract, they are not without cost, morbidity, mortality,
and signiﬁcant reduction in quality of life [70].
5.2.1. Preoperative Endoscopic Management. More than a
decade ago, randomized controlled trials showed superior
outcomes for standard open bile duct surgery as compared
to the endoscopic (ERCP/EST) treatment of CBDS [71].
ERCP/EST was performed with leaving the gallbladder in
situ in patients with preoperative cholangitis or pancreatitis,
older than 80 years of age, substantial comorbidity and
where CBD stones were discovered. Although the success
rate for stone clearance in isolated ERCP treatment is up
to 87% to 97%, up to 25% of patients require two or
more ERCP treatment [72]. This method is associated with
morbidity and mortality rates of 5% to 11% and 0.7% to
1.2%, respectively [73, 74]. Schreurs et al. showed 75%–84%Gastroenterology Research and Practice 5
patients undergoing ERCP/EST had no symptoms with up
to 70-month followup [75]. Complications of ERCP include
bleeding,duodenalperforation,cholangitis,pancreatitis,and
bile duct injury [76] .M o r e o v e r ,E R C Pi sn o tp o s s i b l ei n3 %
to 10% of all patients [77].
Endoscopic balloon dilation of the papilla has been
advocated as an alternative method to EST, in comparison to
this procedure is easier [78], has lower bleeding rate [79, 80],
less disruption of function to the sphincter of Oddi [81].
In comparison to EST, the rate of pancreatitis is higher
than EST and is not the procedure of choice for patients
undergoing stone extraction [82]. Weinberg et al. reviewed
several randomised clinical trials comparing endoscopic
balloon dilation versus EST for the removal of CBDS and
reported that endoscopic balloon dilation is less successful
than EST. In these cases, endoscopic balloon dilation was
done, respectively, in patients with coagulopathy, and at risk
for infection [83].
It is important to ensure adequate biliary drainage in
patients with CBDS that have stoned not yet extracted.
Therefore, short-term use of a biliary stent followed by
further endoscopy or surgical treatment is advocated [84].
For patients over 70 years of age or with debilitating disease,
biliary stenting has also been examined as an alternative to
the endoscopic method [85]. Biliary stenting as a “bridge” to
further therapy is recommended, as is its use as a deﬁnitive
treatmentforCBDSshouldberestrictedtopatientswhohave
limited life expectancy or are judged by a surgeon to be at
prohibitive surgical risk [84].
5.2.2. Laparoscopic Common Bile Duct Exploration. The
successful laparoscopic management of CBD stones depends
on several factors including surgical expertise, adequate
equipment, the biliary anatomy, and the number and size of
CBD stones [86]. With advancing technology and minimally
invasive surgery, laparoscopic biliary surgery has become
safe, eﬃcient, and cost eﬀective [87–89]. Laparoscopic
common bile duct exploration (LCBDE) was associated with
successful stone clearance rates ranging from 85% to 95%,
a morbidity rate of 4%–16% and a mortality rate of around
0%–2% [90, 91]. Laparoscopic exploration is very eﬀective
for clearing diﬃcult CBD stones. Tai et al. reported that the
clearance rate was 100%, and no recurrence was discovered
during a mean followup period of 16 months [76]. Golipour
et al. showed LCBDE to be an eﬀective procedure as the
initial modality of management for acute gallstone cholan-
gitis [92]. Complications from this method include CBD
laceration, stricture formation and bile leak [93]. Patients
treated with LCBDE had a signiﬁcantly shorter hospital
stay and lower hospital costs as compared with ERCP/EST
[88].
During laparoscopic cholecystectomy, if CBDSs are
found with IDUS, IOC, or other modalities, LCBDE can
be performed. There are two primary methods for LCBDE:
trans-cystic (via the cystic duct) and trans-ductal (via
choledochotomy). If CBDS are detected at the time of
laparoscopic cholecystectomy, the best treatment is a trans-
cystic laparoscopic approach during the same operation.
Table 2: Eﬀective and important factors in CBD stones approach
[70].
Factor Trans-cystic
approach
Trans-ductal
approach
Single stone Yes Yes
Multiple stones Yes Yes
Stones < 6mm diameter
each Yes Yes
Stones > 6mm diameter
each No Yes
Intrahepatic stones No Yes
Diameter of cystic duct
< 4mm No Yes
Diameter of cystic duct
> 4mm Yes Yes
Diameter of common bile
duct < 6mm Yes No
Diameter of common bile
duct > 6mm Yes Yes
Cystic duct
entrance—lateral Yes Yes
Cystic duct
entrance—posterior No Yes
Cystic duct
entrance—distal No Yes
Inﬂammation—mild Yes Yes
Inﬂammation—marked Yes No
Suturing ability—poor Yes No
Suturing ability—good Yes Yes
If this fails, alternate approaches such as intraoperative or
postoperative ERCP/EST, laparoscopic choledochotomy, or
open CBDE may be used [94]. A trans-cystic approach is
generally used for small stones in a small bile duct whereas
trans-ductal approach is preferred for large occluding stones
inalargeduct,intrahepaticstones,oraminisculeortortuous
cystic duct [95]. Selection of the diﬀering approaches is
inﬂuenced by several factors [70]( Table 2).
LCBDE-Trans-CysticApproach. Inthetrans-cysticapproach,
100–200mL isotonic sodium chloride solution with 1–2mg
glucagon (for relaxation of Oddi’s sphincter) is used to irri-
gate the CBD in an attempt to ﬂush small stones through the
sphincter of Oddi or out through the opening in the cystic
duct. If this is not successful, a helical basket can be passed
over a guide wire through the cystic duct to extract stones
under ﬂuoroscopic guidance [96]. Today, LCBDE under
ﬂuoroscopic guidance seems to be the procedure of choice.
If this procedure fails, a choledochoscope (≤10Fr) should
be subsequently attempted in order to remove the stones
under direct sight [96]. There is only little data regarding the
use of choledochoscopy in the treatment of CBDS [97]. If
the CBD stone is larger than the lumen of the cystic duct,
the cystic duct can be balloon-dilated. This dilation should
never be larger than the internal diameter of the CBD [98].6 Gastroenterology Research and Practice
A ﬂexible choledochoscope can be passed into the peritoneal
cavity through a midaxillary port and the CBD examined
under direct sight. The CBD should be kept inﬂated with
isotonic sodium chloride solution for better visualization.
Intraluminal stones can be extracted with a basket under
direct vision using the working port of the scope. A Segura-
type stone basket is advanced via the working channel of the
scope beyond the stone and then opened. As the basket is
pulled backwards and simultaneously rotated, the stone is
ensnared[99].Acholangiogramorultrasoundshouldalways
be performed to conclusively demonstrate clearance of the
duct [96]. The outcome of the transcystic method proved
to be consistent with the goals of a laparoscopic approach:
minimal morbidity, no T-tube, no drain, and a rapid return
to normal activity in most cases [70].
Other novel transcystic approaches include balloon
dilatation of the sphincter of Oddi and antegrade sphinc-
terotomy. Balloon dilatation of the sphincter of Oddi can be
performed when all other techniques have failed to clear the
stones.Ariskexistsfordevelopingmildpancreatitiswiththis
method (15% in one series) [100]. Therefore, this technique
should be avoided in patients with pre-existing pancreatitis,
CBD dyskinesia, or sphincter anomalies. Successful tran-
scystic duct clearance has been described in 80%–98% of
patients in a recent series [101, 102]. Complications such as
infection and pancreatitis have been reported in 5%–10%
of patients, with a mortality rate of 0%–2%. The duration
of hospitalization following an uncomplicated transcystic
duct stone extraction is the same as that for laparoscopic
cholecystectomy alone, averaging approximately 1–2 days.
The main advantage of the transcystic approach is that it
avoids the need for choledochotomy [96].
LCBDE-Trans-Ductal Approach. If the transcystic approach
fails, we recommend laparoscopic choledocholithotomy.
Laparoscopic choledocholithotomy can be accomplished
with a variety of techniques. Choledocholithotomy may
involve performing a number of technical maneuvers such
as dilation of the distal CBD, balloon catheter manipulation,
basket manipulation with or without ﬂuoroscopic guidance,
choledochoscopic manipulations [100, 103]a sw e l la sI O C .
After the stones are removed under endoscopic visualization,
the ductotomy is usually closed either primarily or over
an appropriately sized T-tube. The indication for T-tube
insertion is decompression of the duct in patients with resid-
ual distal obstruction, ductal imaging in the postoperative
period and providing an access route for the removal of
residual CBD stones [70]. Most authors prefer a longitudinal
choledochotomy over a distance of approximately 1–1.5cm,
a 14-French latex T-tube (or larger), and closed over a 16-
French T-tube using 4-0 monoﬁlament absorbable sutures.
Some centers use transcystic tubes (C-tube) or antegrade
stenting with choledochorrhaphy for CBD drainage [104,
105]. C-tube drainage via the cystic duct following CBD
exploration would seem to be the preferred choice of
treatment for patients who require choledochotomy because
of large multiple stones in the CBD using this technique
[106].
Management of T-tubes in the postoperative period may
involve bacteremia, dislodgment of the tube, obstruction
by the tube, or fracture of the tube [107]. Broad-spectrum
antibiotic coverage while the T-tube is in situ may be
necessary. The patient can generally be discharged 2–4
days postoperatively. T-tube cholangiography should be
performed before removal of the tube (6–18 days postopera-
tively).RemovalofT-tubeshasbeensuggestedasearlyas5–6
days postoperatively and as late as 4–5 weeks after surgery.
Retained stones demonstrated by T-tube cholangiography
may be eﬀectively removed percutaneously after allowing
maturation of the T-tube tract. Percutaneous extraction
is successful in more than 95% of patients with retained
stones, otherwise postoperative ERCP can be required [96].
Despite the advantages of T-tube drainage and because of
the potential complications of T-tube placement, primary
closure of the CBD without drainage has been advocated by
some authors in open biliary tract surgery [108]. Shorter
operative times and lengths of hospital stay have been
observed with primary closure. No increase in bile leakage
or peritonitis has been noted with primary closure in
the open literature. Higher patient satisfaction has also
been associated with primary closure [70]. Some studies
proposed that choledochotomy with primary laparoscopic
closure of the CBD is safe, eliminates the need for T-tube
placement, and reduces operating time and postoperative
morbidity [109, 110]. Yamazaki et al. reported signiﬁcant
diﬀerences in hospital stay between primary closure and
T-tube insertion (18.3 days versus 31.5 days) [111]. In
other study, Leida et al. showed in patient with primary
closure of the CBD that the time until return to work
(12.6 ±5.1v e r s u s2 0 .4 ±13.2 days) was signiﬁcantly shorter.
Hospital expenses were signiﬁcantly lower and the incidence
of postoperative complications (15% versus 27.5%) and
specially biliary complications (10% versus 20%) were
signiﬁcantly lower than in the T-tube drainage patients
[112].
5.2.3. Postoperative Evaluation and Management. Postopera-
tiveERCPisusedasatreatmentmodalityforCBDSclearance
when LCBDE failed or retained stones are discovered after an
operation (2.5%) [113]. If secondary ERCP fails, clinicians
must be ready for laparoscopic or open exploration. Percu-
taneous transhepatic therapies can be considered for CBDS
under TUS guidance in selected patients [114]. Extraction
of stones, sphincterotomy, or percutaneous drainage can be
performed using this method [115, 116]. New approaches
have been performed which exclude ERCP, such as past
gastric surgery. The most common gastric surgery presently
performed is the Roux-Y gastric bypass. In which, a small
gastric pouch is created and anastomosed to a limb of the
jejunum[114].Themajorityofthestomach,duodenum,and
proximal jejunum are bypassed by this method. Combined
laparoscopic surgical and endoscopic procedures have also
been described. Endoscopic access can be achieved via a gas-
trostomy or jejunostomy [117, 118]. The endoscope can also
be passed into the abdomen during surgical management,
and an ERCP can be performed in the standard technique.Gastroenterology Research and Practice 7
T h e s ep r o c e d u r e sh a v eb e e nd e s c r i b e di nf e wc a s er e p o r t s
[114].
5.2.4. Open Common Bile Duct Exploration. When LCBDS
and postoperative ERCP have failed, the surgeon must use
the open approach to surgery. Martin et al. reported open
surgery as being more successful and being lower mortality
than ERCP in CBDS [119]. There are two options for open
common bile duct exploration: choledochoenterostomy or a
sphincterotomy. Surgeon experience should therefore dictate
which one is performed [120]. Some authors prefer chole-
dochoenterostomy for CBD greater than 2cm in diameter
in order to create a large opening between the bile duct and
intestine.
Sphincterotomy consists of incising the distal part of
the sphincter musculature over a length of approximately
1cm. This incision should not extend beyond the outer
wall of the duodenum [96]. After the choledochotomy, a
catheter or dilator is passed distally and a Kocher maneuver
is performed, then duodenotomy is performed at the level of
the ampulla. The dilator is advocated to bring the ampulla
into the operative ﬁeld, where it is then incised suﬃciently
along the anterosuperior border (opposite the pancreatic
duct oriﬁce) to permit removal of the impacted calculus
[96].
Choledocoenterostomy is the most commonly performed
as a side-to-side choledochoduodenostomy, usually in the
setting of a dilated CBD with multiple stones [96], a
recurrence of CBDS in the Vater’s papilla occurred after
ES and dilated CBD (≥2.0cm). These patients require
drainage for good long-term results without recurrence
of jaundice or cholangitis [121]. The technique most
commonly used is that of a side-to-side hand-sutured
anastomosis between the supraduodenal common bile duct
and the duodenum [122] .AK o c h e rm a n e u v e ri sp e r f o r m e d
and the distal CBD is exposed. Choledochotomy is made
within 2-3cm of the lateral border of the duodenum. A
diamond-shaped anastomosis is performed with interrupted
absorbable sutures. One potential complication is the “sump
syndrome” caused by food or other debris caught in the
distal CBD [123]. This complication is rare (1%) and can
be managed with ERC/ES [124]. The alternative operation,
transection choledochoduodenostomy, excludes the distal
(transpancreatic) segment of the bile duct from the end-
to-side anastomosis of the transected common bile duct
with the second part of the duodenum. The long-term
results of this procedure are excellent [122]. Another optimal
option is the choledochojejunostomy with a roux-en-Y
loop.
5.2.5. Electrohydraulic Lithotripsy (EHL). EHL uses direct
high voltage to generate a shockwave through a liquid
medium to fragment the bile duct stone. The procedure has
beenperformedsuccessfullyundercholangioscopicguidance
[10, 125] or under ﬂuoroscopic control using a balloon
catheter [126]. Typically, its use is reserved for cases of
CBD packed with multiple faceted stones or a single large
impacted stone. For EHL to be successful the stone must
be targeted under direct sight, otherwise there is increased
risk of damaging the bile duct wall [127]. This method is
rarely used because of its high potential for tissue damage
and bleeding.
5.2.6. Extracorporeal Shockwave Lithotripsy (ESWL). ESWL
was ﬁrst used treating gallstones in 1980s following its
successful use in fragmenting renal calculi [10]. ESWL
involves the percutaneous administration of sound waves
directed at the liver and bile duct. It is not performed during
endoscopy, but rather before an ERCP in hopes of shattering
large stones into smaller, more manageable fragments [127].
European studies evaluating ESWL report duct clearance
rates of 83% to 90%, but its acceptance in the United States
has been slow [127, 128].
5.2.7. Laser Lithotripsy. Laser lithotripsy uses ampliﬁed light
energy at a particular wavelength, which is focused into a
single beam and directed onto a stone within the bile duct
[10]. Laser lithotripsy can be performed under direct vision
with cholangioscopy using mini scopes or can be performed
under ﬂuoroscopic control using standard equipment [10].
The success rate of duct clearance for retained CBDS using
laser lithotripsy is between 64% and 97% in several studies
[129].
5.2.8. Dissolving Solutions. Table 3 shows several types of
solutions that are used for dissolving gallstones and CBD
stones. These solutions have few toxic side eﬀects and do not
cause irritation of the biliary tree. Every dissolution therapy
will last for several weeks, therefore the ideal solvent has
not yet been produced [5]. The use of ursodeoxycholic acid
(UDCA) and chenodeoxycholic acid has only been shown
to dissolve cholesterol-containing stones. Approximately 85–
95% of patients in the Western World will have cholesterol
stones. Continuing therapy with UDCA appeared to prevent
recurrence of gallbladder microlithiasis [130]. Methyl-Tert-
butyl-Ether (MTBE) is an excellent cholesterol solvent that
hasbeenshowntoworkfaster,butitistoxictoliverandduo-
denal mucosa. It has been proposed by several studies that
using dissolution in combination with endoscopic retrieval
or lithotripsy has better outcomes [5, 131, 132]. Katsinelos et
al. suggested that UDCA does not seem to contribute to the
reduction in stones’ size or stones’ fragmentation during the
endoprosthetic procedure [133].
Recurrence of CBD stones after ES is reported in a
considerable number of patients (6–21%), resulting from
de novo primary stone formation or recurrent secondary
migration from the gallbladder [134]. Primary CBDSs are
associated with bactobilia and delayed bile-duct clearance
which is indicated by CBD dilation. Endoscopic reinterven-
tion is safe and usually easy to perform. Surgery should
only be reserved for intractable cases. In selected patients, an
underlying lithogenic bile composition (low-phospholipid-
associated cholelithiasis) should be identiﬁed and preven-
tive medical treatment with UDCA can be considered
[134].8 Gastroenterology Research and Practice
Table 3: Types of dissolving solutions for the treatment of CBDS
[5].
Substance Date Author(s) Country
Ether 1891 Walker [135] England
Turpentine 1908 Wright [136] England
Chloroform 1945 Narat and Cipolla
[137]
USA
Heparin saline 1971 Gardner et al. [138] USA
Na Cholate 1972 Way et al. [139] USA
Chenodeoxydrolic
acid
1972 Danziger et al. [140] USA
Ursodeoxycholate 1975 Makino et al. [141] USA
Mono-octanoin 1981 Gadacz [142] Japan
Methyl-tert-butyl
ether
1985 Allen et al. [143] USA
6. Conclusion
Today, management of CBDS is a complicated procedure for
the treating medical stone. Ultrasonography and ERCP are
routine diagnostic modalities in most centers, but clinicians
can often choose from other low-invasive modalities such
as MRCP or CT. LCBDE (trans-cystic or trans-ductal) is a
standard method with a high eﬃcacy and low morbidity
and mortality for the treatment of CBDS in most centers.
Pre- or postoperative ERCP/EST can be use as an alternative
method. We recommend that for patients with CBDS, ERCP
should be performed as a ﬁrst step and in the event of
failureLCBDEcanbeperformed.Itshouldnotbeforgotthat
the open approach always remains as a ﬁnal option when
others modalities have failed. Electrohydraulic lithotripsy,
extracorporeal shockwave lithotripsy, laser lithotripsy, and
dissolving solutions have especial indications and more
clinical trial in this area must be performed.
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